Azafaros, a Netherlands-based clinical-stage biotech firm focused on rare lysosomal storage disorders, has successfully completed a â¬132M Series B funding round aimed at advancing its drug development, specifically for conditions like Niemann-Pick Type C (NPC) and GM1/GM2 diseases. Led by Jeito Capital and co-led by Forbion Growth, the investment underscores a strong belief in the potential of Azafaros's pipeline, particularly its candidate nizubaglustat, which is poised for Phase 3 trials. New board members from leading investors will help steer the company through its next phases in clinical development.
Azafaros has been impressive in its execution with nizubaglustat poised to begin Phase 3 clinical development and the potential to significantly improve the lives of NPC and GM1/GM2 patients.
Azafaros exemplifies the kind of science-driven, mission-focused company we seek to back. Nizubaglustat has the potential to fundamentally change the treatment landscape for rare genetic diseases.
Collection
[
|
...
]